214 related articles for article (PubMed ID: 28991670)
1. Follow-on products for treatment of multiple sclerosis in Latin America: An update.
Correale J
J Neurol Sci; 2017 Oct; 381():153-159. PubMed ID: 28991670
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod.
Correale J; Chiquete E; Boyko A; Beran RG; Strauch JB; Milojevic S; Frider N
Drug Des Devel Ther; 2016; 10():2109-17. PubMed ID: 27418809
[TBL] [Abstract][Full Text] [Related]
3. Biological and nonbiological complex drugs for multiple sclerosis in Latin America: regulations and risk management.
Carrá A; Macías Islas MA; Tarulla A; Bichuetti DB; Finkelsztejn A; Fragoso YD; Árcega-Revilla R; Cárcamo Rodríguez C; Durán JC; Bonitto JG; León R; Oehninger Gatti C; Orozco G; Vizcarra Escobar D
Expert Rev Neurother; 2015 Jun; 15(6):597-600. PubMed ID: 25924772
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R
J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455
[TBL] [Abstract][Full Text] [Related]
5. The emergence of follow-on disease-modifying therapies for multiple sclerosis.
Moss BP; Cohen JA
Mult Scler; 2019 Oct; 25(12):1560-1565. PubMed ID: 31074707
[TBL] [Abstract][Full Text] [Related]
6. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies.
Castañeda-Hernández G; Szekanecz Z; Mysler E; Azevedo VF; Guzman R; Gutierrez M; Rodríguez W; Karateev D
Joint Bone Spine; 2014 Dec; 81(6):471-7. PubMed ID: 24956990
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars in IBD: from theory to practice.
Danese S; Bonovas S; Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol; 2017 Jan; 14(1):22-31. PubMed ID: 27729659
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars: Rationale and current regulatory landscape.
Olech E
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
[TBL] [Abstract][Full Text] [Related]
9. The role of generic medicines and biosimilars in oncology in low-income countries.
Renner L; Nkansah FA; Dodoo AN
Ann Oncol; 2013 Sep; 24 Suppl 5():v29-32. PubMed ID: 23975702
[TBL] [Abstract][Full Text] [Related]
10. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
11. [Biosimilars--opportunity or threat?].
Swierkot J
Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
[TBL] [Abstract][Full Text] [Related]
12. An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
Gran-Ruaz S; Mani A; O'Quinn S
Mult Scler; 2017 Dec; 23(14):1824-1829. PubMed ID: 29095099
[TBL] [Abstract][Full Text] [Related]
13. Development and regulation of biosimilars: current status and future challenges.
Tsiftsoglou AS; Ruiz S; Schneider CK
BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
[TBL] [Abstract][Full Text] [Related]
14. [Biosimilars: regulatory status for approval].
Herrero Ambrosio A
Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
[TBL] [Abstract][Full Text] [Related]
15. Development of biosimilars.
Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of the high cost drug program on an example of the interferon treatment of multiple sclerosis].
Vlasov IaV; Dolgikh GT; Dolgilh TA; Kurapov MA; Nilov AI; Tarasova SV; Churakov MV; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):66-73. PubMed ID: 23528597
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
18. The biosimilar insulin landscape: current developments.
Lavalle-González FJ; Khatami H
Postgrad Med; 2014 Oct; 126(6):81-92. PubMed ID: 25414937
[TBL] [Abstract][Full Text] [Related]
19. The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?
Crommelin DJ; Broich K; Holloway C; Meesen B; Lizrova Preiningerova J; Prugnaud JL; Silva-Lima B
Mult Scler; 2016 Aug; 22(2 Suppl):47-59. PubMed ID: 27465615
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars in inflammatory bowel disease.
Gargallo CJ; Lué A; Gomollón F
Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
